Please select from the following list of abstracts, representing the presentations given in Stockholm 2008 (IWWM-5) Session 4:
International Waldenström Macroglobulinemia Prognostic Index Project. Pierre Morel, Olivier Tournilhac, Jérôme Tamburini, Alain Duhamel, Jacques Vargaftig, Bénédicte Hivert and Veronique Leblond. Services d’Hématologie des Hôpitaux de Lens, Clermont Ferrand, Pitié-Salpêtrière, Paris. Centre d’Etude et de Recherche en Informatique Médicale de Lille, FRANCE.
Prognostic relevance of 6q deletion in Waldenström’s Macroglobulinemia. Chang H, Qi C, Trieu Y, Jiang A, Xu W, Young KH, Chesney A, Jani P, Wang C, Reece D, Chen C. University Health Network, Toronto. University of Wisconsin, USA. Sunnybrook Health Sciences Center, Toronto. Thunder Bay Health Sciences Center, Ontario. Mount Sinai Hospital, Toronto, CANADA.
Plasma cell differentiation in indolent lymphomas originated from marginal zones. Jean Feuillard, Centre Hospitalier Universitaire (CHU) Dupuytren and Faculté de Médecine, Université de Limoges, FRANCE.
Prognostication in young and elderly patients with WM. E. Kastritis, K. Zervas, P. Repoussis, E. Michali, A. Zomas, A. Simeonidis, E. Terpos, S. Delimbassi, A. Vassou, D. Gika, M.A. Dimopoulos, on behalf of the Greek Myeloma Study Group, Athens, GREECE.
Complexities of assessing response in WM. Roger Owen, HMDS Laboratory, The Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM.
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as, plasmapheresis, in patients with Waldenström's Macroglobulinemia. B. T. Ciccarelli, G. Yang, E. Hatjiharissi, J. D. Soumerai, Z. R. Hunter, L. Ioakimidis, C. J. Patterson, R. J. Manning, L. Xu, S. Adamia, S. P. Treon; Dana-Farber Cancer Institute, Boston, MA, USA.
